Announced
Bavarian Nordic to acquire the travel vaccine portfolio of Emergent BioSolutions for $380m.
Synopsis
Bavarian Nordic, a biotechnology company, agreed to acquire the travel vaccine portfolio of Emergent BioSolutions, a developer of vaccines, for $380m. “This acquisition adds not only to our commercial portfolio and reinforces our leading position in travel vaccines, but it also strengthens our pipeline," Paul Chaplin, Bavarian Nordic President and CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.